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Abstract Comparison of two methods to detect circulating
tumor cells (CTC) CytoTrack and CellSearch through recov-
ery of MCF-7 breast cancer cells, spiked into blood collected
from healthy donors. Spiking of a fixed number of EpCAM
and pan-cytokeratin positive MCF-7 cells into 7.5 mL donor
blood was performed by FACSAria flow sorting. The samples
were shipped to either CytoTrack or CellSearch research fa-
cilities within 48 h, where evaluation of MCF-7 recovery was
performed. CytoTrack and CellSearch analyses were per-
formed simultaneously. Recoveries of MCF-7 single cells,
cells in clusters, and clusters were determined. The average
numbers of MCF-7 cells/cells in clusters/clusters recovered
from blood by the CytoTrack and CellSearch methods were
103±5.9/27±7.9/11±3.5 (95 % CI) and 107±4.4/20±7.1/10
±3.5, respectively, with no difference between the two
methods (p=0.37/p=0.23/p=0.09). Overall, the recovery of
CytoTrack and CellSearch was 68.8±3.9 %/71.1±2.9 %, re-
spectively (p=0.58). In spite of different methodologies,
CytoTrack and CellSearch found similar number of CTCs,
when spiking was performed with the EpCAM and pan
cytokeratin-positive cell line MCF-7. The results suggest that
CytoTrack and CellSearch have similar abilities to identify
CTC in vitro.
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Introduction
Cancer is a disease, which frequently have serious conse-
quences. Cancer dissemination from the primary tumor to
lymph nodes, distant organs, or bones leads to a poorer prog-
nosis. Cancer may spread through invasion of the adjacent
tissue or the lymphatic system, or through the blood circula-
tion [1]. Subsequently, there can be circulating cancer cells in
the blood stream of a cancer patient. These cells are known as
circulating tumor cells (CTC), and it is possible to isolate,
enumerate, and characterize them based on their molecular
and genetic characteristics. Normally, the CTC will not be
detected in the peripheral blood of a healthy individual. How-
ever, CTC detection may be indicative of cancer dissemina-
tion and can consequently be used for cancer prognosis.
Therefore, CTC are potential biomarker for the surveillance
of cancer progression [2, 3].
The detection of CTC in cancer patients has been pioneered
by the CellSearch™ system, with numerous clinical studies
that show a strong prognostic value of CTC detection in pa-
tients. The presence of CTC confers a poorer prognosis for the
patient and shorter progression free (PFS) and overall survival
(OS) in breast cancer [4] and ovarian cancer [5] as well as a
shorter overall survival in colorectal cancer [6] and prostate
cancer [7]. The collection of a CTC sample can be performed
at any time before or during therapy and indicates subsequent
rapid progression and mortality of the patients [8]. This has
spurred several prospective clinical trials that examine the
utility of CTC analysis in patient management. STIC CTC
METABREAST is a two-armed trial comparing conventional
treatment versus CTC-driven treatment, where patients with
CTCs in the circulation receive chemotherapy as compared to
hormone therapy in the CTC-negative patients. In the
SWOG0500 trial, patients positive for CTC both before and
after the first two cycles of chemotherapy are being treated by
either continued chemotherapy (standard arm) or an
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alternative chemotherapy regimen to be decided by the oncol-
ogist (CTC arm). In the CirCe01 trial, patients positive for
CTC after first cycle of new chemotherapy are shifted to next
line therapy (CTC arm). In the treat CTC trial, patients with
non-metastatic disease and the presence of HER2 non-
amplified primary tumors that have at least one CTC by anal-
ysis of 15 mL of blood (two tubes) are treated with HER2
antibody therapy (Trastuzumab, CTC arm). In the DETECT
III trial, patients with one or more CTC positive for HER2 are
treated by the HER2 and EGFR tyrosine kinase inhibitor
Lapatinib (CTC arm) [3]. In addition, a range of studies in-
cludes CTC retrospectively as a prognostic marker or a marker
for monitoring treatment effect, with 1535 completed or on-
going studies including CTC registered on Clinicaltrials.org
(2nd of July 2014).
The clinical application of CTC enumeration and charac-
terization is thus under investigation and most studies are per-
formed with the CellSearch method. However, the chosen
methodology for CTC detection can have a major impact on
the result, depending on sensitivity, specificity, and detection
limit, and therefore the different methodologies should be
compared with respect to their performance [2].
In the current study, the CTC detection methods
CytoTrack™ and CellSearch are compared with an in vitro
assessment using spiking experiments with the breast cancer
cell line MCF-7 positive for both epithelial cell adhesion mol-
ecule (EpCAM) and pancytokeratin. The MCF-7 cell line was
selected to avoid differences due to antibody specificities
when comparing the two technologies.
Methods and materials
Cells were cultured and spiked into blood from healthy donors
after receiving written consent in accordance with the Decla-
ration of Helsinki and approved by the national Danish Ethics
Committee (protocol no. H-4-2014-056) for analysis by either
CellSearch (Janssen Diagnostics, LLC, Raritan, NJ, USA for-
merly Veridex) or by CytoTrack (CytoTrack ApS, Lyngby,
Denmark) after 48 h as outlined below.
Cell culture
The human breast adenocarcinoma cell line MCF-7 was ob-
tained from American Type Culture Collection (ATCC, Ma-
nassas, VA, USA) and cultured in Dulbecco’s Modified Eagle
(DMEM)-GlutaMAX™ medium (Gibco, Grand Island, NY,
USA), supplemented with 1 % penicillin-streptomycin and
10 % heat-inactivated fetal calf serum. The culture was grown
in cell culture flasks in a humidified atmosphere containing
5 % CO2 at 37 °C. Cell culture was washed with Dulbecco’s
phosphate buffered saline without calcium and magnesium
(DPBS, Gibco) followed by harvesting with TrypLe Express
(Gibco).
Blood sample collection
Peripheral blood (7.5 mL) was collected from healthy donors
into evacuated CellSave™ Preservative Tubes (Veridex LLC,
Raritan, NJ, USA) containing EDTA and a cellular preserva-
tive. Blood samples were maintained at room temperature and
spiked within 48 h.
Blood spiking experiments
Six separate experiments were performed spiking five 7.5 mL
blood samples with 150 MCF-7 cells as previously described
[9] and analyzed by either CytoTrack or CellSearch. Addition-
ally, a control sample was included in every experiment.
CytoTrack
Sample processing
Spiked blood samples were centrifuged at 2500g for 15 min
and the layer with leukocytes and tumor cells was transferred
to 15 mL conical Falcon tubes (VWR Bie & Berntsen,
Soeborg, Denmark). Remaining red blood cells were lysed
with FACS lysing solution (BD Biosciences) and the samples
centrifuged at 2500g for 15 min. Thereafter, cells were stained
using CTC Stain™ comprising a mixture of anti-CD45/Near
InfraRed (NIR) antibody (clone: HI30), anti-pancytokeratin/
Green antibody (clone: AE1/AE3), 4′,6-diamidino-2-
phenylindole (DAPI), and a permeabilization buffer
(Intrastain, DAKO, Glostrup Denmark). Cells were then
washed with phosphate buffered saline (PBS) with 1 % BSA
and resuspended in H2O, transferred to a CytoDisc
™, air-
dried, and mounted using VectaShield Hard Set Mounting
Medium (Vector Laboratories Inc., Burlingame, CA, USA)
and covered with a CytoCover™.
Analysis
Stained cells on the CytoDisc were enumerated by scanning
using a CytoTrack CT4 Scanner. Scanning was performed
within 1 week as previously described [9]. Briefly, green fluo-
rescence events were recorded and listed in a hotspot table.
Recorded events were visually inspected by the operator in the
green channel, and an image gallery was automatically gener-
ated using the DAPI, green, and NIR channels from positions
on the CytoDisc with suspected CTC (Fig. 1a). The image
gallery was analyzed using the following morphologic criteria
to identify CTC: Nearly round and size >4 μm with visible
DAPI-positive nucleus with at least 50 % association with the
cytoplasm, cytokeratin positive, and CD45 negative. The
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definition of CTC in the current study is similar to the defini-
tion used by other methods analyzing for CTC [2, 10–12].
CellSearch
Sample processing
CellSearch CTC analysis was carried out on the CellSearch
System consisting of the Autoprep™ and Celltracks Analyzer
II™ systems. Suspected CTC were quantified using
CellSearch Epithelial Cell Kit, ref 7900000, according to the
manufacturer’s instructions. In short, 7.5 mL of whole blood
was mixed with 6 mL of buffer and centrifuged at 800g for
10 min before placement in the semi-automated Autoprep
system. Plasma was aspirated and suspected CTC of epithelial
origin were immune-magnetically enriched using ferrofluid-
conjugated antibodies specific for EpCAM. For identification
of CTC permeabilization buffer, phycoerythrin (PE) conjugat-
ed antibodies specific for cytokeratins 8, 18, and 19 and DAPI
for associated nuclei stain were added to the enriched cells.
Residual leukocytes with positive DAPI were negatively dif-
ferentiated from suspected CTC by addition of anti-CD45
antibodies conjugated with APC. After enrichment, staining,
incubation, and washing, the Autoprep resuspended and trans-
ferred the cells to a magnetic cartridge that orient the ferrofluid
bound cells in a monolayer focal plan for analysis in the
Celltracks Analyzer II four color fluorescence microscope.
Analysis
Within 24 h, the magnetic cartridge was placed in the
CellSearch Autoprep system and the semi-automated fluores-
cence microscope captured four color images (PE, DAPI,
APC, and DiOC) of the entire magnetic cartridge focal plan.
A software algorithm built an image gallery of objects positive
for PE, cytokeratins, and DAPI nuclei stain (Fig. 1b). A
single-trained operator makes the final selection of expected
CTC from the image gallery to ensure that all CTC criteria
stated in the CellSearch scanning paragraph were1 met.
Statistical analysis
Data were tested by the D’Agostino-Pearson K2 test Gaussian
distribution [13] and were not proven different from a Gauss-
ian distribution. Mean, SD, 95 % confidence intervals (95 %
CI), and percent coefficient of variation (CV%) were calculat-
ed using Excel (Microsoft, Redmond, Washington, USA).
The two methods were compared pairwise and with regard
to intra- and inter-serial runs by two-tailed t test with a signif-
icance level of p<0.05.
Results
Results from each experiment are shown in Table 1 and Fig. 2.
The average numbers of MCF-7 cells/cells in clusters/clusters
recovered from blood by the CytoTrack and CellSearch
methods were 103±5.9/27±7.9/11±3.5 (95 % CI) and 107±
4.4/20±7.1/10±3.5 (95 % CI), respectively, with no differ-
ence between the two methods (p=0.37/p=0.23/p=0.09).
Overall, the recovery of MCF-7 cells by CytoTrack and
CellSearch was 68.8±3.9 %/71.1±2.9 %, respectively
(p=0.58). Overall, the intra assay variability of CytoTrack
and CellSearch was 11.2 % (range 11.3–12.5 %) and 7.9 %
(range 3.2–7.9 %), respectively. A test for intra assay var-
iability for CytoTrack and CellSearch showed no differ-
ence between the three spiking experiments (p>0.05, data
not shown) in either method.
Fig. 1 Image galleries of aCytoTrack and bCellSearch. Cells are stained
with the epithelial marker pan-cytokeratin (left), the nuclear marker DAPI
(center), and the leukocyte marker CD45 (right). CytoTrack images were
recorded with a color camera, and CellSearch images were recorded with
a black and white camera
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Discussion
The analysis of CTC with high sensitivity and specificity is
challenging, as it is required to pinpoint individual CTC in a
7.5 mL blood sample with more than 50 million leukocytes
[14]. In the current study, the two technologies CytoTrack and
CellSearch are compared under in vitro conditions. CytoTrack
is a novel method recently described [9] and the CellSearch
CTC Test is FDA-approved as an aid in the monitoring of
patients with metastatic breast, colon, and prostatic cancer
[15]. It should be pointed out that the CytoTrack technology
has as yet not been clinically validated although work is on-
going with serial measurements of CTC among patients with
metastatic breast cancer [16]. The two technologies use very
different approaches. Whereas the CellSearch approach is a
‘closed’ automated, FDA cleared system intended for clinical
monitoring, the CytoTrack approach is an ‘open’ manual re-
search system which allow for studying other markers for
CTC enumeration and characterization of CTC. In CytoTrack,
all nucleated cells in a blood sample are DAPI-stained, immu-
nostained with antibodies against cytokeratin and CD45 and
cytosmeared over a CytoDisc. Afterwards, fluorescence
scanning is performed, suspected CTC on the disc are identi-
fied, and an image gallery is created for manual validation. In
CellSearch, plasma is removed and magnetic sorting of
EpCAM positive cells is carried out, subsequently the cells
are stained for cytokeratins 8, 18, and 19, DAPI and CD45 and
placed in a magnetic cartridge where image galleries of
suspected CTC events are recorded for manual validation.
The different approaches could in principle give rise to signif-
icantly different abilities to detect CTC, with CytoTrack rely-
ing on cytokeratin signal to detect cells and CellSearch depen-
dent on both EpCAM and cytokeratin expression. In the cur-
rent study of in vitro detection of MCF-7, a cytokeratin- and
EpCAM-positive cell line, the two CTC technologies
CytoTrack and CellSearch have similar recovery of cells
spiked into blood (69 vs. 71 %, p=0.58). It should be noted
that the recoveries were estimated on the basis of FACSAria
spiking counts of cells in blood samples, a count which was
previously estimated to result in actual spiking numbers
around 74 % of the expected FACSAria spiking cell counts
[9]. The spiking was performed with care taken to obtain
single cells; however, a fraction of cell clusters contained
two or more cells. Therefore, the results of both CTC number
(total number of both single cells and cells in clusters), cells in
clusters (only cells in clusters counted), and clusters (the num-
ber of clusters counted) were recorded. Both CTC, cells in
clusters and clusters had similar recoveries by CytoTrack
and CellSearch. CellSearch, however, has a lower variability
(CV%) in the analysis, which may be due to the automated
procedures in CellSearch versus manual procedures in the
CytoTrack analysis.
Nonetheless, CytoTrack proves to have a recovery and a
reproducibility matching that of CellSearch, which is promis-
ing with regard to future studies including test of CTC in
clinical samples from breast, colon, and prostate cancer pa-
tients. Moreover, further markers, both surface and intracellu-
lar phenotypic and genetic, can be explored to improve the
performance of the CytoTrack across different cell types. A
Table 1 Number of CTC found in spiking experiments with CytoTrack and CellSearch
CytoTrack CellSearch
CTC1 Exp. 1 Exp. 2 Exp. 3 Total Exp. 1 Exp. 2 Exp. 3 Total
Mean 104 104 101 103 116 102 104 107
Range 93–122 88–123 89–122 88–123 107–122 98–107 95–117 95–122
n 5 5 5 15 42 5 5 14
95 % CI 10,3 11,1 11,0 5,9 6,4 2,9 7,2 4,4
Recovery % 69,2 70,0 67,1 68,8 77,3 68,1 69,2 71,1
CV 11.3 % 12.1 % 12.5 % 11.2 % 5.6 % 3.2 % 7.9 % 7.9 %
1CTC are defined as nearly round size >4 μm with visible DAPI-positive nucleus with at least 50 % association with the cytoplasm, pancytokeratin
positive, and CD45 negative
2One sample failed in CellSearch Exp.1
Fig. 2 Number of CTC, cells in clusters, and clusters found with
CytoTrack and CellSearch. Numbers are means of three spiking
experiments to a total of 15 samples (CytoTrack) and 14 samples
(CellSearch)
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specific challenge for CellSearch is when CTC undergo epi-
thelial to mesenchymal transition (EMT) as the EpCAM ex-
pression is reduced or not present in mesenchymal cells which
makes it difficult to detect these cells [17, 18]. The possibility
to explore markers in cells of mesenchymal origin thus seems
especially interesting since if markers for EMT are present on
the surface or inside CTC it is possible for CytoTrack to find
the cells. This is the first in vitro comparison between
CytoTrack and CellSearch, and considerable work is required
for further comparison. CytoTrack is a novel technology and
thus there is a need for more in vitro studies of cells from
different cancer types spiked into blood and in vitro studies
with EpCAM or CK weak cells to investigate the limits of the
two technologies. Also, studies of basic clinical performance
in various cancers as well as studies of intra- and inter-lab and
inter-observer variability are required. In conclusion, our data
indicate that CytoTrack and CellSearch despite fundamentally
different technologies may yield similar results when using a
cell line selected to match the markers used by both technol-
ogies. Our investigation provides a basis for further studies
using either different cells lines and/or different CTCmarkers.
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